... (semaglutide) injection, for subcutaneous use. (2022). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial.
Оземпик Ozempic - Новини
... (semaglutide) injection, for subcutaneous use. (2022). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial.